Phase I trial HMR code: 25-001

Phase I trial HMR code: 25-001 [The full scientific title will be published within 30 months after the end of the trial]

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN11493807

Enrollment

Registered

2025-05-16

Start date

2025-06-03

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers Other

Interventions

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy human volunteer

Exclusion criteria

Exclusion criteria: The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Design outcomes

Primary

Measure	Time frame
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.	—

Secondary

Measure	Time frame
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.	—

Countries

England, United Kingdom

Contacts

Public ContactPh1 Department

phase1@drfalkpharma.de+49 (0)76115140

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026